Literature DB >> 28446416

[Research progress of depression and the application of esketamine].

Fang-Bo Lin1, De-Ren Hou, Qiu-Ping Tang.   

Abstract

OBJECTIVE: The pathogenesis and etiology of still remain unknown. Current evidence suggests that the occurrence of depression may be related to a reduced secretion of neurotransmitters, neuronal apoptosis, inflammation, intestinal flora and other factors. Although the commonly used antidepressants such as SSRIs, SNRIs, NaSSA, and SARIs produce some therapeutic effects, they fail to relieve the full spectrum of the symptoms of depression. In recent years, esketamine was found to produce a potent and a long-lasting antidepressant effect by acting on the NMDA receptors. Herein the authors review the progress in the study of the pathogenesis and drug therapies of depression, the efficacy of esketamine treatment and the underlying mechanism, and the prospect of esketamine treatment. Currently the mechanism of the antidepressant effect of esketamine remains indeterminate and its clinical application is limited, but its effect in rapidly alleviating the symptoms of depression suggests its bright prospect for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28446416      PMCID: PMC6744095     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  22 in total

Review 1.  Increased expression of the anti-apoptotic protein Bcl-xL in the brain is associated with resilience to stress-induced depression-like behavior.

Authors:  Nikolay N Dygalo; Tatyana S Kalinina; Veta V Bulygina; Galina T Shishkina
Journal:  Cell Mol Neurobiol       Date:  2012-01-26       Impact factor: 5.046

2.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

3.  Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus.

Authors:  Maryam Ardalan; Ali H Rafati; Jens R Nyengaard; Gregers Wegener
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

Review 4.  A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Authors:  Marie Naughton; Gerard Clarke; Olivia F O'Leary; John F Cryan; Timothy G Dinan
Journal:  J Affect Disord       Date:  2013-12-10       Impact factor: 4.839

5.  Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study.

Authors:  H J Conradi; J Ormel; P de Jonge
Journal:  Psychol Med       Date:  2010-10-08       Impact factor: 7.723

Review 6.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

7.  Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion.

Authors:  Kim Gilbert; Jessica Arseneault-Bréard; Fabio Flores Monaco; Alexanne Beaudoin; Thierno Madjou Bah; Thomas A Tompkins; Roger Godbout; Guy Rousseau
Journal:  Br J Nutr       Date:  2012-10-15       Impact factor: 3.718

8.  Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression.

Authors:  Sameer Hassamal; Margaret Spivey; Ananda K Pandurangi
Journal:  Clin Neuropharmacol       Date:  2015 Sep-Oct       Impact factor: 1.592

9.  Correlation between the human fecal microbiota and depression.

Authors:  A Naseribafrouei; K Hestad; E Avershina; M Sekelja; A Linløkken; R Wilson; K Rudi
Journal:  Neurogastroenterol Motil       Date:  2014-06-01       Impact factor: 3.598

10.  Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Authors:  A A Nierenberg; M M Husain; M H Trivedi; M Fava; D Warden; S R Wisniewski; S Miyahara; A J Rush
Journal:  Psychol Med       Date:  2009-05-22       Impact factor: 7.723

View more
  3 in total

1.  Antidepressant-like effects of the Guanxin Danshen formula via mediation of the CaMK II-CREB-BDNF signalling pathway in chronic unpredictable mild stress-induced depressive rats.

Authors:  Weijie Xie; Xiangbao Meng; Yadong Zhai; Tianyuan Ye; Ping Zhou; Fengwei Nan; Guibo Sun; Xiaobo Sun
Journal:  Ann Transl Med       Date:  2019-10

Review 2.  Panax Notoginseng Saponins: A Review of Its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology.

Authors:  Weijie Xie; Xiangbao Meng; Yadong Zhai; Ping Zhou; Tianyuan Ye; Zhen Wang; Guibo Sun; Xiaobo Sun
Journal:  Molecules       Date:  2018-04-17       Impact factor: 4.411

3.  Antidepressant effects of total alkaloids of Fibraurea recisa on improving corticosterone-induced apoptosis of HT-22 cells and chronic unpredictable mild stress-induced depressive-like behaviour in mice.

Authors:  Zhongmei He; He Yu; Hong Wu; Lili Su; Kun Shi; Yan Zhao; Ying Zong; Weijia Chen; Rui Du
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.